NCCN Adds Pacritinib to MPN Guidelines

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms to include the oral JAK inhibitor pacritinib as a first-line treatment for high-risk patients with myelofibrosis with platelet counts less than 50 x 10⁹/L who are not candidates for transplant. The recommendation was given a Category 2A designation.

Pacritinib was also included as a Category 2A designation as a second-line treatment for lower- and higher-risk patients with myelofibrosis with platelet counts of 50 x 10⁹/L or more who are not candidates for transplant.

Pacritinib is an oral kinase inhibitor with activity against JAK2, mutant JAK2^V617F form, and FLT3. The drug was approved under the US Food and Drug Administration’s accelerated approval program based on spleen volume reduction.

Source: CTI BioPharma Corp, April 2022